{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:18:24Z","timestamp":1768011504130,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.humpath.2020.09.016","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:45:57Z","timestamp":1602146757000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-3347","authenticated-orcid":false,"given":"Daniel S.","family":"Socha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8761-3170","authenticated-orcid":false,"given":"Xiaoxian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-728X","authenticated-orcid":false,"given":"Juraj","family":"Bodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-2687","authenticated-orcid":false,"given":"Lisa","family":"Durkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2020.09.016_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"317","author":"Swerdlow","year":"2017"},{"issue":"9","key":"10.1016\/j.humpath.2020.09.016_bib2","first-page":"864","article-title":"Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia","volume":"11","author":"Lai","year":"1998","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2020.09.016_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2003-06-1901","article-title":"Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma","volume":"103","author":"Zhao","year":"2004","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.humpath.2020.09.016_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/10428199809058352","article-title":"BCL-X and the apoptotic machinery of lymphoma cells","volume":"28","author":"Xerri","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.humpath.2020.09.016_bib5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2007-09-110601","article-title":"Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways","volume":"111","author":"Ruiz-Vela","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.humpath.2020.09.016_bib6","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1182\/blood.V97.12.3902","article-title":"MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes","volume":"97","author":"Zhou","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humpath.2020.09.016_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2141.2005.05954.x","article-title":"Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma","volume":"132","author":"Michels","year":"2006","journal-title":"Br J Haematol"},{"issue":"43","key":"10.1016\/j.humpath.2020.09.016_bib8","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.humpath.2020.09.016_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.humpath.2020.09.016_bib10","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/emboj.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.humpath.2020.09.016_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2141.2003.04086.x","article-title":"Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes","volume":"120","author":"Horsman","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.humpath.2020.09.016_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations","volume":"114","author":"Leich","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.humpath.2020.09.016_bib13","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/blood-2011-06-361972","article-title":"MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype","volume":"118","author":"Leich","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.humpath.2020.09.016_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.14684","article-title":"Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment","volume":"178","author":"Vogler","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.humpath.2020.09.016_bib15","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.humpath.2014.06.005","article-title":"BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma","volume":"45","author":"Kendrick","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2020.09.016_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/path.1689","article-title":"Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation","volume":"205","author":"Schraders","year":"2005","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2020.09.016_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/00313021003631296","article-title":"Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody","volume":"42","author":"Masir","year":"2010","journal-title":"Pathology"},{"issue":"9","key":"10.1016\/j.humpath.2020.09.016_bib18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.humpath.2013.02.004","article-title":"The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-\"negative\" grade 1\/2 follicular lymphomas","volume":"44","author":"Adam","year":"2013","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2020.09.016_bib19","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.humpath.2020.09.016_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/leu.2012.367","article-title":"MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma","volume":"27","author":"Wenzell","year":"2013","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.humpath.2020.09.016_bib21","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in\u00a0vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin Canc Res"},{"issue":"2","key":"10.1016\/j.humpath.2020.09.016_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Del Gaizo Moore","year":"2013","journal-title":"Canc Lett"},{"issue":"5","key":"10.1016\/j.humpath.2020.09.016_bib23","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/cdd.2008.25","article-title":"A novel paradigm for rapid\u00a0ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells","volume":"15","author":"Vogler","year":"2008","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.humpath.2020.09.016_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ejcb.2017.09.002","article-title":"BH3-only protein BIM: an emerging target in chemotherapy","volume":"96","author":"Shukla","year":"2017","journal-title":"Eur J Cell Biol"},{"issue":"12","key":"10.1016\/j.humpath.2020.09.016_bib25","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3109\/10428194.2014.900759","article-title":"Disruption of chromosomal locus 1p36 differentially modulates TAp73 and \u0394Np73 expression in follicular lymphoma","volume":"55","author":"Hassan","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.humpath.2020.09.016_bib26","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/10428194.2018.1529310","article-title":"BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma","volume":"60","author":"Ito","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.humpath.2020.09.016_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.humpath.2020.09.016_bib28","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1158\/1535-7163.MCT-09-0685","article-title":"Bim-targeted cancer therapy: a link between drug action and underlying molecular changes","volume":"8","author":"Akiyama","year":"2009","journal-title":"Mol Canc Therapeut"},{"issue":"1","key":"10.1016\/j.humpath.2020.09.016_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CJI.0000000000000102","article-title":"Differential expression of Bcl-2 family proteins determines the sensitivity of human follicular lymphoma cells to dexamethasone-mediated and anti-BCR-mediated apoptosis","volume":"39","author":"Adem","year":"2016","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.humpath.2020.09.016_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.10384","article-title":"The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma","volume":"92","author":"Koster","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.humpath.2020.09.016_bib31","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2020.09.016_bib32","first-page":"5735","article-title":"EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys27 acetylation in the BIM gene promoter and enhancers","volume":"14","author":"Huang","year":"2017","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.humpath.2020.09.016_bib33","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41418-019-0410-x","article-title":"T-cell receptor signal strength and epigenetic control of Bim predict memory CD8+ T-cell fate","volume":"27","author":"Li","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.humpath.2020.09.016_bib34","unstructured":"FDA granted accelerated approval to tazemetostat for follicular lymphoma. US Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma."}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:37:14Z","timestamp":1758645434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817720301970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":34,"alternative-id":["S0046817720301970"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2020.09.016","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2020.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}